Second, nc886 is suppressed and PKR is activated in a number of cancer cell lines and clinical specimens, for example, in CCA, breast cancer, head-neck cancer, acute myeloid leukemia, ovarian cancer, lung cancer, etc. ([8,12,15]; references in [12]; YSL, unpublished data). The gene discussed is EIF2AK2; the disease is cholangiocarcinoma.